We are live on ! Find out more
SCM

Silverarc Capital Management Portfolio holdings

AUM $980M
1-Year Est. Return 470.8%
This Fund
S&P 500
This Quarter Est. Return
+12.11%
1 Year Est. Return
+470.8%
3 Year Est. Return
+3,352.06%
5 Year Est. Return
+7,957.7%
10 Year Est. Return
–
AUM
$177M
AUM Growth
+$177M
Cap. Flow
+$20.1M
Cap. Flow %
11.35%
Top 10 Hldgs %
37.39%
Holding
117
New
21
Increased
27
Reduced
33
Closed
35

Top Buys

Rank Stock Value
1
COGT icon
Cogent Biosciences
COGT
+$3.68M
2
FULC icon
Fulcrum Therapeutics
FULC
+$3.52M
3
CERS icon
Cerus
CERS
+$3.5M
4
ARVN icon
Arvinas
ARVN
+$3.29M
5
NXTC icon
NextCure
NXTC
+$3.18M

Top Sells

Rank Stock Value
1
DRNA
Dicerna Pharmaceuticals, Inc.
DRNA
+$5.49M
2
MORF
Morphic Holding, Inc. Common Stock
MORF
+$2.79M
3
MSAC
Medicus Sciences Acquisition Corp. Class A Ordinary Share
MSAC
+$2.54M
4
RNLX
Renalytix plc American Depositary Shares
RNLX
+$2.3M
5
CRIS icon
Curis
CRIS
+$1.54M

Sector Composition

Rank Sector Weight
1 Healthcare 89.56%
2 Financials 5.83%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
MLTX icon
26
MoonLake Immunotherapeutics
MLTX
$1.56B
$2.22M 1.26%
223,906
-10,114
-4% -$101K
CLDX icon
27
Celldex Therapeutics
CLDX
$2.94B
$2.06M 1.17%
38,243
+28,322
+285% +$1.33M
ELOX
28
DELISTED
Eloxx Pharmaceuticals, Inc. Common Stock
ELOX
$2.05M 1.16%
31,496
-15,692
-33% -$968K
BGMS
29
Bio Green Med Solution Inc
BGMS
$4.86M
$2.05M 1.16%
108
+36
+50% +$692K
SGEN
30
DELISTED
Seagen Inc. Common Stock
SGEN
$2M 1.13%
11,749
+6,017
+105% +$936K
ERAS icon
31
Erasca
ERAS
$6.15B
$1.98M 1.12%
+93,122
New +$1.92M
OTIC
32
DELISTED
Otonomy, Inc.
OTIC
$1.95M 1.1%
1,017,048
+63,614
+7% +$108K
VTGN icon
33
VistaGen Therapeutics
VTGN
$9.98M
$1.94M 1.1%
23,591
+3,073
+15% +$267K
MCRB icon
34
Seres Therapeutics
MCRB
$45M
$1.91M 1.08%
13,742
+10,546
+330% +$2.06M
BNTC icon
35
Benitec Biopharma
BNTC
$414M
$1.78M 1.01%
29,295
+1,809
+7% +$119K
CYTK icon
36
Cytokinetics
CYTK
$10.6B
$1.76M 1%
+49,309
New +$1.45M
VRDN icon
37
Viridian Therapeutics
VRDN
$2.2B
$1.75M 0.99%
106,078
+77,679
+274% +$1.14M
LHDX
38
DELISTED
Lucira Health, Inc. Common Stock
LHDX
$1.68M 0.95%
+220,758
New +$1.86M
ZNTL icon
39
Zentalis Pharmaceuticals
ZNTL
$332M
$1.59M 0.9%
23,855
-10,870
-31% -$627K
STXS icon
40
Stereotaxis
STXS
$133M
$1.57M 0.89%
291,696
-14,708
-5% -$111K
JNCE
41
DELISTED
Jounce Therapeutics, Inc. Common Stock
JNCE
$1.55M 0.88%
208,559
-42,085
-17% -$261K
CGEN icon
42
CALL
Compugen
CGEN
$212M
$1.48M 0.84%
+248,000
New +$1.66M
PYPD icon
43
PolyPid
PYPD
$78.2M
$1.43M 0.81%
6,108
+956
+19% +$233K
ADMS
44
DELISTED
Adamas Pharmaceuticals
ADMS
$1.41M 0.8%
288,042
-250,702
-47% -$1.22M
EYPT icon
45
EyePoint Inc
EYPT
$999M
$1.35M 0.76%
129,290
-113,019
-47% -$1.08M
VRAY
46
DELISTED
ViewRay, Inc.
VRAY
$1.33M 0.75%
185,035
+90,647
+96% +$572K
DCPH
47
DELISTED
Deciphera Pharmaceuticals, Inc. Common Stock
DCPH
$1.27M 0.72%
37,249
-8
-0% -$255
BIIB icon
48
Biogen
BIIB
$30.9B
$1.24M 0.7%
+4,389
New +$1.44M
CGEN icon
49
Compugen
CGEN
$212M
$1.22M 0.69%
203,532
-5,581
-3% -$37.4K
ARNA
50
DELISTED
Arena Pharmaceuticals Inc
ARNA
$1.11M 0.63%
18,581
-1,996
-10% -$118K
1
2
3 4 5

Similar funds

BIP
Blueprint Investment Partners Greensboro, North Carolina $980M AUM 27.19% 1-Year Est. Return
MVM
Medicxi Ventures Management St. Helier, Jersey $982M AUM 210.17% 1-Year Est. Return
MFWP
Mosaic Family Wealth Partners St. Louis, Missouri $977M AUM 19.09% 1-Year Est. Return
FCM
Fortis Capital Management Bellevue, Washington $977M AUM 17.17% 1-Year Est. Return
PE
PSG Equity Boston, Massachusetts $977M AUM 13.39% 1-Year Est. Return
KL
KIM LLC Wichita, Kansas $976M AUM 0.91% 1-Year Est. Return
GFP
Gryphon Financial Partners Columbus, Ohio $976M AUM 23.05% 1-Year Est. Return
ADIC
Abu Dhabi Investment Council Abu Dhabi, United Arab Emirates $975M AUM

Silverarc Capital Management's Q3 2021 Portfolio in Review

As of Q3 2021, Silverarc Capital Management held 117 positions worth $177M, up 78,789% from $224K the previous quarter. Its ten largest holdings account for 37% of the portfolio.

Silverarc Capital Management deployed $20.1M of net new capital in Q3 2021, opening 21 new positions and adding to 27 existing holdings. Its largest new stake was Fulcrum Therapeutics: 185,691 shares worth $5.24M.

By sector, the portfolio is most concentrated in Healthcare at 90% of assets, up from 79% a quarter earlier, followed by Financials.

On the sell side, the largest reduction was Dicerna Pharmaceuticals, Inc., an estimated $5.49M trimmed.

  • Silverarc Capital Management's largest Q3 2021 buy was Fulcrum Therapeutics: 185,691 shares worth $5.24M.
  • Silverarc Capital Management added most to Cogent Biosciences in Q3 2021, an estimated $3.68M increase.
  • Silverarc Capital Management's biggest Q3 2021 reduction was Dicerna Pharmaceuticals, Inc., cutting an estimated $5.49M.
  • Silverarc Capital Management fully exited Chinook Therapeutics, Inc. Common Stock in Q3 2021, selling an estimated $12.8K.
  • Silverarc Capital Management's ten largest holdings make up 37% of its $177M portfolio in Q3 2021.
  • Silverarc Capital Management opened 21 new positions and closed 35 in Q3 2021.
  • Silverarc Capital Management's portfolio value rose 78,789% quarter-over-quarter to $177M.

Based on Silverarc Capital Management's 13F filing for Q3 2021, filed 15 Nov 2021.